Biotech entity
Every one of those 1 sits in a single category, clinical-trial. COSMOS Trial is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Epigenetic Clocks, all published on March 9, 2026.
Last mentioned: Mar 9, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. COSMOS Trial is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Epigenetic Clocks, all published on March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 17 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Epigenetic Clocks. Shared-story counts are live from our verified record — not editorial picks.
Biological Aging Analysis
New data reveals daily multivitamins significantly slow epigenetic aging clocks.
Cognitive & Clinical Results
Initial findings on memory and cardiovascular outcomes published with mixed results.
COSMOS Trial Launch
Large-scale randomized trial begins investigating cocoa extract and multivitamins.
A prespecified analysis of the large-scale COSMOS trial has found that daily multivitamin-multimineral supplementation significantly slows markers of biological aging in older adults. The study provides robust clinical evidence that standard nutritional interventions can influence cellular longevity and epigenetic health beyond simple deficiency prevention.
Epigenetic Clocks is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
